GLUD1P2: A Potential Drug Target and Biomarker (G414212)

Target Name: GLUD1P2

NCBI ID: G414212

GLUD1P2

Other Name(s): GLUD1P7 | glutamate dehydrogenase 1 pseudogene 2 | GLUDP7 | GLUDP2 | Glutamate dehydrogenase 1 pseudogene 2

GLUD1P2: A Potential Drug Target and Biomarker

GLUD1P2 (GLUD1P7) is a protein that is expressed in various tissues throughout the body, including the brain, spleen, and skeletal muscles. It is a member of the GLUT family of proteins, which are involved in the regulation of cell signaling and protein synthesis.

While GLUD1P2 has been identified as a potential drug target and biomarker for various diseases, including cancer, it is still a relatively unexplored protein. However, research has shown that GLUD1P2 plays a crucial role in several important cellular processes, including cell signaling, protein synthesis, and inflammation.

GLUD1P2 functions as a negative regulator of the protein kinase B-cell src/FAK signaling pathway. This pathway is involved in the regulation of cell proliferation, differentiation, and survival, and is a key factor in the development and maintenance of cancer. By regulating the activity of FAK, GLUD1P2 helps to prevent the uncontrolled growth and proliferation of cancer cells.

GLUD1P2 has also been shown to play a role in the regulation of muscle growth and protein synthesis. When muscle cells are stimulated to grow, GLUD1P2 is activated and helps to coordinate the production of new muscle protein. This is important for muscle growth and maintenance, as well as for maintaining muscle strength and function.

GLUD1P2 is also involved in the regulation of inflammation, which is a critical part of the immune response. When the body is exposed to an infection or injury, GLUD1P2 helps to coordinate the production of pro-inflammatory cytokines, such as TNF-alpha and IL-1. These cytokines help to recruit and activate immune cells, which are essential for fighting off the invading microorganisms or repairing damaged tissue.

GLUD1P2 is a protein that has been identified as a potential drug target for several diseases, including cancer, cardiovascular disease, and neurological disorders. For example, studies have shown that GLUD1P2 is overexpressed in various types of cancer, including breast, lung, and ovarian cancer. This suggests that targeting GLUD1P2 with drugs that can inhibit its activity could be an effective way to treat these diseases.

In addition to its potential as a drug target, GLUD1P2 is also a promising biomarker for several diseases. For example, GLUD1P2 has been shown to be elevated in the blood of people with multiple sclerosis, a progressive neurodegenerative disorder. This suggests that GLUD1P2 may be a useful biomarker for tracking the progression of this disease.

GLUD1P2 is also a potential target for other diseases, including cardiovascular disease and neurological disorders. For example, studies have shown that GLUD1P2 is overexpressed in the brains of people with Alzheimer's disease, a progressive neurodegenerative disorder. This suggests that targeting GLUD1P2 with drugs that can inhibit its activity could be an effective way to treat this disease.

In conclusion, GLUD1P2 is a protein that is involved in several important cellular processes, including cell signaling, protein synthesis, and inflammation. It is a potential drug target and biomarker for several diseases, including cancer, cardiovascular disease, and neurological disorders. Further research is needed to fully understand the role of GLUD1P2 in these processes and to develop effective treatments for these diseases.

Protein Name: Glutamate Dehydrogenase 1 Pseudogene 2

The "GLUD1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLUD1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets